+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the effects of a medicine called survodutide on adults living with type 2 diabetes who have a body mass index BMI of 23 kgm2 or higher. The study aims to find out whether survodutide helps control blood sugar levels compared to a placebo. This phase III trial includes participants who manage their diabetes with diet and exercise, diabetes tablets, or insulin injections, reflecting different treatment backgrounds. Participants are divided into three parts based on their current diabetes treatment Part A includes those using diet and exercise only, Part B includes those on oral diabetes medications without insulin, and Part C includes those using insulin injections with or without diabetes tablets. Within each part, participants are randomly assigned to one of three groups placebo, low-dose survodutide, or high-dose survodutide. The medicine or placebo is injected under the skin once a week while participants continue their regular diabetes treatment. Over about 14 months, participants attend up to 12 in-person visits and receive at least 9 phone calls for monitoring. Doctors regularly check blood sugar levels using HbA1c tests and other laboratory tests, and monitor overall health and any changes. The main measure is the change in HbA1c from the start to Week 41, while additional outcomes include blood sugar levels, body weight, cholesterol, kidney function, and insulin dose changes. Results will compare survodutide groups with placebo to assess its impact on diabetes management.

Age: 18Years +All GendersPhase 3
101 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
E

Actively Recruiting

Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD, a condition that causes symptoms like leg pain due to poor blood flow. The study is a phase 3 randomized, double-blind, placebo-controlled trial aiming to better understand how this treatment impacts walking ability and quality of life in this population. Participation is expected to last about 58 weeks. Participants are randomly assigned to receive either orforglipron or a placebo, both taken orally once daily. The study compares these two groups to assess changes in walking distances and other health measures over the course of the trial. This design helps evaluate the medications effect compared to no active treatment. During the study, participants undergo assessments including measuring maximum and pain-free walking distances, vascular quality of life via questionnaire, the six-minute walk test, blood markers like high-sensitivity C-reactive protein, and systolic blood pressure. These measurements occur at the start and after 52 weeks of treatment. Safety and effectiveness are monitored throughout, with overall participation lasting nearly a year.

Age: 18Years +All GendersPhase 3
169 locations
L

Actively Recruiting

Researchers are investigating maridebart cafraglutide for people with obesity or overweight to evaluate its long-term effects on weight management, safety, and tolerability. This trial is an extension of a previous study trial 20210181 and aims to provide more information about how the drug works over an extended period. It is a phase 3, randomized, double-blind study sponsored by Amgen. Participants will receive different doses of maridebart cafraglutide or placebo depending on their treatment in the previous trial. Some will continue with low dose every 4 weeks, others will be re-randomized to receive medium or high doses on schedules of every 4, 8, or 12 weeks, or placebo injections every 4 weeks. Participants who had placebo before will undergo a dose-escalation phase before starting the high dose treatment. During the study, participants will be monitored for changes in body weight, waist circumference, quality of life, and any side effects or adverse events over about 48 weeks of treatment. The trial will assess how well weight loss is maintained and record any treatment-emergent adverse events up to 60 weeks. Participants will have regular visits for injections and safety assessments throughout the study period.

Age: 18Years - 99YearsAll GendersPhase 3
92 locations
I

Actively Recruiting

Researchers are evaluating the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. This trial compares intensive lowering of serum phosphate towards the normal level 1.50 mmolL with a more liberal target 2.0 to 2.5 mmolL to see if it reduces death or major cardiovascular events, and improves physical health and quality of life. The study is a large, international, randomized controlled trial sponsored by The University of Queensland. Participants will be randomly assigned to one of two groups one targeting a liberal serum phosphate level where phosphate-lowering medications are only prescribed if levels exceed 2.5 mmolL, and the other aiming for an intensive target with medications used to lower phosphate to normal levels. The choice and dose of phosphate binders will be decided by the treating physician and participant. The treatment period is expected to last up to five years. During the study, participants will be monitored for cardiovascular events, death, physical health, fatigue, quality of life, and patient satisfaction. Assessments include tracking the time to cardiovascular death or major cardiovascular events, all-cause death, and quality of life using the EQ5D-5L measure. Data will be collected throughout the treatment period, with safety and effectiveness evaluated over five years.

Age: 18Years +All GendersPhase Not Applicable
126 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations
I

Actively Recruiting

The trial investigates treatments for bloodstream infection caused by Staphylococcus aureus SAB, which can be life-threatening with a 15-30% death rate within three months. This international, multi-center randomized adaptive platform trial aims to find the best treatment options to reduce mortality within 90 days of infection. The trial adapts over time by assigning more patients to treatments that show better outcomes and removing less effective options. Participants receive various antibiotic treatments depending on their group. These include intravenous vancomycin or daptomycin, flucloxacillin or cloxacillin, cefazolin, or benzylpenicillin, with dosages adjusted for kidney function or illness severity. Some receive adjunctive drugs like clindamycin, and others may switch from intravenous to oral antibiotics if eligible after 7 or 14 days. Additionally, some participants undergo PETCT scans as part of the study. During the study, participants are monitored closely with blood cultures, temperature checks, and clinical assessments to track infection clearance and complications. Researchers measure all-cause mortality at 90 days as the primary outcome, along with other outcomes such as survival at earlier time points, hospital stay length, microbiological treatment failure, serious reactions, and antibiotic use. Safety and health economic data are also collected to evaluate treatments comprehensively throughout the trial.

All AgesAll GendersPhase 4
161 locations